<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="letter"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Diabetes Care</journal-id><journal-id journal-id-type="hwp">diacare</journal-id><journal-id journal-id-type="pmc">dcare</journal-id><journal-id journal-id-type="publisher-id">Diabetes Care</journal-id><journal-title-group><journal-title>Diabetes Care</journal-title></journal-title-group><issn pub-type="ppub">0149-5992</issn><issn pub-type="epub">1935-5548</issn><publisher><publisher-name>American Diabetes Association</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">22110180</article-id><article-id pub-id-type="pmc">3220841</article-id><article-id pub-id-type="publisher-id">1772</article-id><article-id pub-id-type="doi">10.2337/dc11-1772</article-id><article-categories><subj-group subj-group-type="heading"><subject>Diabetes Care Electronic Pages</subject><subj-group><subject>Online Letters: Comments and Responses</subject></subj-group></subj-group></article-categories><title-group><article-title>Comment on: Hellemons et al. Initial Angiotensin Receptor Blockade&#x02013;Induced Decrease in Albuminuria Is Associated With Long-Term Renal Outcome in Type 2 Diabetic Patients With Microalbuminuria: A Post Hoc Analysis of the IRMA-2 Trial. Diabetes Care 2011;34:2078&#x02013;2083</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name><surname>Davidson</surname><given-names>Mayer B.</given-names></name><degrees>MD</degrees></contrib><aff>From the Department of Internal Medicine, Charles Drew University of Medicine and Science, Los Angeles, California</aff></contrib-group><author-notes><corresp id="cor1">Corresponding author: Mayer B. Davidson, <email>mayerdavidson@cdrewu.edu</email>.</corresp><fn id="fn1"><p>Clinical trial reg. no. NCT00907374, <ext-link ext-link-type="uri" xlink:href="http://clinicaltrials.gov">clinicaltrials.gov</ext-link>.</p></fn></author-notes><pub-date pub-type="ppub"><month>12</month><year>2011</year></pub-date><pub-date pub-type="epub"><day>14</day><month>11</month><year>2011</year></pub-date><volume>34</volume><issue>12</issue><fpage>e188</fpage><lpage>e188</lpage><permissions><copyright-statement>&#x000a9; 2011 by the American Diabetes Association.</copyright-statement><copyright-year>2011</copyright-year><license license-type="open-access"><license-p>Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. See <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by-nc-nd/3.0/">http://creativecommons.org/licenses/by-nc-nd/3.0/</ext-link> for details.</license-p></license></permissions><self-uri xlink:title="pdf" xlink:type="simple" xlink:href="e188.pdf"/></article-meta></front><body><p>Hellemons et al. (<xref ref-type="bibr" rid="B1">1</xref>) in a post hoc analysis of the Irbesartan in Patients with Type 2 Diabetes and Microalbuminuria (IRMA)-2 trial provocatively showed that the initial reduction of microalbumiuria with an angiotensin receptor blocker (ARB) was independently associated with renoprotection (i.e., independent of blood pressure changes). Antihypertensive medication was removed for a 3-week run-in period before the ARB was (re)introduced. If these results could be confirmed in a randomized controlled trial (RCT) it would imply that aggressive reduction of microalbuminuria should be attempted&#x02014;an approach not currently recommended by the American Diabetes Association (<xref ref-type="bibr" rid="B2">2</xref>). This might be a difficult goal to accomplish clinically given the marked day-to-day intraindividual variability (33&#x02013;61%) of microalbuminuria (<xref ref-type="bibr" rid="B3">3</xref>,<xref ref-type="bibr" rid="B4">4</xref>). We could not lower established microalbuminuria in an RCT pilot study in patients already treated with submaximal doses of an ACE inhibitor by maximizing the doses of a combination of benazepril plus losartan compared with 10 mg of the ACE inhibitor over a mean of 12 months (<xref ref-type="bibr" rid="B5">5</xref>). In our run-in period, patients were kept on 10 mg of benazepril. This might be an important factor in designing future real-world RCTs to test the hypothesis generated by the post hoc analysis of the IRMA-2 trial (<xref ref-type="bibr" rid="B1">1</xref>).</p></body><back><ack><p>No potential conflicts of interest relevant to this article were reported.</p><p>Parts of this study were presented in poster form at the 69th Scientific Sessions of the American Diabetes Association, New Orleans, Louisiana, 5&#x02013;9 June 2009.</p></ack><ref-list><title>References</title><ref id="B1"><label>1</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hellemons</surname><given-names>ME</given-names></name><name><surname>Persson</surname><given-names>F</given-names></name><name><surname>Bakker</surname><given-names>SJL</given-names></name><etal/></person-group> <article-title>Initial angiotensin receptor blockade&#x02013;induced decrease in albuminuria is associated with long-term renal outcome in type 2 diabetic patients with microalbuminuria: a post hoc analysis of the IRMA-2 trial</article-title>. <source>Diabetes Care</source> <year>2011</year>;<volume>34</volume>:<fpage>2078</fpage>&#x02013;<lpage>2083</lpage><pub-id pub-id-type="pmid">21788629</pub-id></mixed-citation></ref><ref id="B2"><label>2</label><mixed-citation publication-type="journal"> <collab>American Diabetes Association</collab> <article-title>Standards of medical care in diabetes&#x02014;2011</article-title>. <source>Diabetes Care</source> <year>2011</year>;<volume>34</volume>(<issue>Suppl. 1</issue>):<fpage>S11</fpage>&#x02013;<lpage>S61</lpage><pub-id pub-id-type="pmid">21193625</pub-id></mixed-citation></ref><ref id="B3"><label>3</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mogensen</surname><given-names>CE</given-names></name></person-group> <article-title>Microalbuminuria as a predictor of clinical diabetic nephropathy</article-title>. <source>Kidney Int</source> <year>1987</year>;<volume>31</volume>:<fpage>673</fpage>&#x02013;<lpage>689</lpage><pub-id pub-id-type="pmid">3550239</pub-id></mixed-citation></ref><ref id="B4"><label>4</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Houillier</surname><given-names>P</given-names></name><name><surname>Coste</surname><given-names>J</given-names></name><name><surname>Froissart</surname><given-names>M</given-names></name></person-group> <article-title>How many measurements to make a decision?</article-title> <source>Clin J Am Soc Nephrol</source> <year>2010</year>;<volume>5</volume>:<fpage>1161</fpage>&#x02013;<lpage>1162</lpage><pub-id pub-id-type="pmid">20558565</pub-id></mixed-citation></ref><ref id="B5"><label>5</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Davidson</surname><given-names>MB</given-names></name><name><surname>Tareen</surname><given-names>N</given-names></name><name><surname>Duran</surname><given-names>P</given-names></name><name><surname>Aquilar</surname><given-names>V</given-names></name><name><surname>Lee</surname><given-names>ML</given-names></name></person-group> <article-title>Aggressive versus low dose inhibition of the renin-angiotensin system for the treatment of microalbuminuria in type 2 diabetic patients: a pilot study [Internet], 2011</article-title>. <source>ISRN Endocrinol</source>. <comment>Available from <ext-link ext-link-type="uri" xlink:href="http://www.isrn.com/journals/endocrinology/2011/696124/">http://www.isrn.com/journals/endocrinology/2011/696124/</ext-link>. Accessed 19 October 2011</comment></mixed-citation></ref></ref-list></back></article>